Biosimilar adalimumab FKB-327 in the treatment of inflammatory bowel disease
Original articleGastroent Hepatol 2020; 74(6): 553–557. doi: 10.48095/ccgh2020553
SummaryLiteraturepdf Milan Lukáš, Martin Vašátko, Martin Lukáš, Martin Kolář, Dana Ďuricová, Naděžda Machková, Karin Malíčková, Veronika HrubáThe selection from international journals
CommentsGastroent Hepatol 2021; 75(2): 173–176.
pdf Irena Míková, Peter Slodička, Tomáš Tichý, Vincent Dansou Zoundjiekpon, Martin KolářSwitch from original to biosimilar adalimumab SB-5 in patients with Crohn‘s disease – long-term results
Original articleGastroent Hepatol 2021; 75(3): 242–251. doi: 10.48095/ccgh2021242
SummaryLiteraturepdf Milan Lukáš, Martin Kolář, J. Reissigová, Milan Lukáš jr., Martin Vašátko, Veronika Hrubá, Naděžda Machková, Kateřina Černá, Dana ĎuricováSwitch from biosimilar infliximab CT-P13 to biosimilar infliximab SB-2 in the long-term maintenance therapy in IBD patients – prospective observational study
Original articleGastroent Hepatol 2023; 77(4): 336–341. doi: 10.48095/ccgh2023336
SummaryLiteraturepdf Jindra Reissigová, Karin Černá , Milan Lukáš jr., Milan Lukáš, Veronika Hrubá, Naděžda Machková, Dana Ďuricová, Martin Kolář, Kateřina Vlková, Lea ČermákováSubcutaneous infliximab in the treatment of refractory Crohn‘s disease patients – a pilot study of drug immunogenicity
Original articleGastroent Hepatol 2023; 77(5): 419–426. doi: 10.48095/ccgh2023419
SummaryLiteraturepdf Karin Černá , Dana Ďuricová, Martin Lukáš, Naděžda Machková, Veronika Hrubá, Kristýna Kaštylová, Katarína Mitrová, Marta Kostrejová, Kristýna Kubíčková, Štěpán Peterka, Martin Kolář, Jakub Jirsa, Gabriela Vojtěchová, Milan LukášAdherence to therapy in patients with inflammatory bowel disease on subcutaneous biologic therapy
Original articleGastroent Hepatol 2024; 78(6): 483–491. doi: 10.48095/ccgh2024483
SummaryLiteraturepdf Martin Kolář, Milan Lukáš